Biotech, in brief

Denmark's trial randomly assigned 511,535 adults either to be offered a bivalent RSV vaccine or not, then counted what happened to both halves. [1]

Nineteen people in the vaccinated half were admitted to hospital with an RSV chest illness. In the other half, sixty-four were. [1]

That is a cut of 70.3%, and the true figure sits somewhere between 49.7% and 83.2%. [1]

RSV is a common winter virus. It gives most people a cold and sends some older people to hospital. Participants averaged 61.5 years old, and 63.2% were 60 or over. [1]

The gain was largest in the oldest group. Among people aged 75 and over, 29 were hospitalised with RSV without the shot and 7 with it. [1]

Hospital admissions of every kind barely moved: 13,470 in the vaccinated half against 13,675 in the other, a 1.3% gap that could be chance. [1]

Deaths from any cause were 610 against 623, which is no difference. [1]

As a check on their own counting, the researchers also tracked flu, which this shot should not touch. It did not: 806 confirmed cases against 792. [1]

Serious side effects were slightly less common in the vaccinated half, 2.0% against 2.2%. Five people in that half developed Guillain-Barre syndrome, a nerve condition. None did in the other. [1]

A second paper published the same week reports how the protection held across two RSV seasons, and a safety analysis of the extended trial went into a cardiology journal on 29 August. [2][3]

A trial this size only works where hospital stays and deaths are already recorded for everybody. Counting 27,145 admissions across both halves needed no clinic visits at all. That is our reading of the design, not a claim in the paper. [1]

Why it matters. Watch whether health systems elsewhere copy the design rather than the finding; the open question the companion paper starts on is how many seasons one dose keeps working. [2]

BioNTech and Genentech ended a phase 2 trial of a personalised cancer vaccine. It was given to people whose bowel cancer had been cut out, and an independent monitoring board found more deaths among them than among those simply watched. [4] BioNTech's shares fell about 7.5%. [4]

Why it matters. It is the mirror image of Merck and Moderna's melanoma win: the same idea, given on its own rather than beside an immune-releasing drug, in a tumour type with few immune cells in it.

Merck paid Moderna $200m in 2016 and another $250m in 2022 to develop a personalised cancer vaccine together, and the two share costs and profits. [5] Moderna's former chief doctor says the field failed for many years before it worked. [5] Nature notes an earlier 157-person trial in 2024 pointed the same way. [6]

Why it matters. The result that moved markets this month was bought a decade ago.

A Dana-Farber oncologist writing in Nature says the melanoma vaccine, intismeran, would be only the second therapeutic cancer vaccine ever approved, after one cleared in 2010. [6] Each shot has to be made for one person from that person's own tumour mutations. [6]

Why it matters. A treatment built one at a time cannot be stockpiled, so the factory clock becomes the patient's clock.

Updated results from the 740-patient AEGEAN trial show durvalumab plus chemotherapy before surgery still delays cancer coming back, with a hazard ratio of 0.69. [7] Overall survival favoured the drug but did not reach statistical significance, at 0.89. [7]

Why it matters. Delaying a return is not the same as living longer, and the second number is the one patients are asking about.

A prespecified analysis of the 241-person VALOR trial found the higher dose of brepocitinib beat a dummy pill on skin disease from week 4 through week 52. [8] Itch nearly stopped in 38.3% of them against 19.0% on placebo. [8]

Why it matters. The pill was approved on 27 August; this is the first detailed look at which symptoms it actually shifts.

The FDA, the US drug regulator, has cleared 36 medicines never approved before during 2026. [9] Three came in six days: a pancreatic cancer drug on 26 August, the dermatomyositis pill on 27 August, and a drug for a rare blood disorder on 28 August. [28][29][30]

Why it matters. The regulator describes each of the three as a first of its kind, in conditions where patients had been relying on drugs meant for something else. [28][29][30]

Researchers at Washington University in St Louis found that opioid-sensitive receptors in the locus coeruleus, the brain's alert centre, hold nerve pain in check. [10] Removing them in mice made the animals more sensitive; putting them back reversed it. [10]

Why it matters. Opioid drugs hit these receptors everywhere in the body, which is where the side effects and the addiction risk come from.

In two groups of over 100 unvaccinated Nigerian adults, antibodies still recognised the original 2020 coronavirus more strongly than the Omicron variant people had recently met. [11] In 93% there was evidence of a pre-Omicron infection. [11]

Why it matters. In heavily vaccinated countries you cannot tell infection-made immunity from vaccine-made immunity, so the question was only answerable where the vaccines had not reached.

Human brain organoids, pea-sized clumps of brain tissue grown from stem cells, were kept alive for five years and aged in the same chemical pattern real brains do. [12] Earlier attempts mostly captured the first weeks of development. [12]

Why it matters. Human brains develop far more slowly than animal ones, which is why the lab version had to be kept going that long to be useful.

Isolated male mice drank more alcohol and isolated females drank less, and a single nerve pathway from the amygdala to the front of the brain tracked the difference. [13] Switching that pathway on raised drinking; switching it off lowered it. [13]

Why it matters. A result that splits by sex is a warning about every study that pooled the two and reported an average.

Researchers are converging on intrinsic capacity, a score built from five things a person can do: thinking, moving, seeing and hearing, mood, and energy. [14] The World Health Organization defined it in 2015. [14]

Why it matters. Anti-ageing treatments have had nothing to be scored against, because counting diseases avoided is slow and counting deaths is slower.

Writing is too recent for evolution to have built a reading centre, so the brain borrows. Brain scans from the Human Connectome Project link reading skill to hearing-related structures that partly run in families. [15]

Why it matters. It offers a mechanism for why some children find reading hard, and why deaf and blind readers get there by other routes.

In 52,445 UK Biobank participants, seven proteins were disturbed in both overweight people and people with ulcerative colitis, an inflammatory bowel disease. [16] All seven held up in a further 37,478 people. [16]

Why it matters. Nobody was recruited for this; the blood was drawn years ago for a different question.

Smoking, high blood pressure and diabetes in middle age each cut the number of years a person is likely to live without dementia, the US National Institutes of Health reported on 25 August. [17] The same week it reported that a coating stops tooth decay in children. [17]

Why it matters. Counting healthy years rather than cases measures the thing people actually live in.

The US National Institute of Allergy and Infectious Diseases published its 2026-2030 plan, built around human immunology: strengthening protective responses, calming harmful ones in allergy and autoimmune disease, and using the gut's microbes. [18][19]

Why it matters. It is the largest single funder of infectious-disease research, so its five-year list shapes what gets studied everywhere.

A comment in Nature Reviews Cancer traces four cancer targets - EGFR, HER2, CDK4/6 and RAS - back to laboratory discoveries made decades before any drug reached a patient. [20]

Why it matters. The pancreatic cancer drug cleared on 26 August attacks RAS, a protein family first described in the early 1980s. [28]

A South African study tested 1,518 people in 327 households twice weekly for flu, whether or not they felt ill, across three seasons. [21] Someone shedding a lot of virus raised the risk to their household by roughly 65% to 95%. [21]

Why it matters. Studies that wait for people to visit a doctor miss infections that never make anyone feel ill, and those turn out to be common.

Researchers built the first working method for editing genes in European beech, a dominant Central European forest tree now under strain from a changing climate. [22] Editing worked in 4.75% to 32.69% of cells, depending on conditions. [22]

Why it matters. Until now there was no way to test which beech genes actually drive drought resilience.

A Nature comment argues that for small or long-neglected patient groups the machinery needed to produce solid statistics is often incomplete or missing, so families end up making their case by telling their own story. [23]

Why it matters. It is the same gap the Danish trial sits on the other side of.

A review sets out the limits of reprogramming the cell's protein-making machinery to read past a faulty stop signal in a gene: the approach struggles when the gene involved is a long one. [24]

Why it matters. Several of the diseases people most want to fix this way, including some muscle diseases, sit in very long genes.

Nature Reviews Drug Discovery highlighted work on a re-engineered immune cell therapy for progressive multiple sclerosis, where existing B-cell drugs leave some patients still relapsing. [25]

Why it matters. It is the same cell therapy that this week put six people's rheumatoid arthritis into remission, aimed at a different disease.

Writing in NEJM Voices, a Cedars-Sinai heart failure specialist argues that a trial reported as a failure usually contains a more specific finding than the headline word carries. [26]

Why it matters. It lands in the week a heart drug and a cancer vaccine were both filed under failure for quite different reasons.

The US National Institutes of Health is offering for licence a weakened live RSV vaccine for young children. Deleting a protein called M2-2 makes the virus copy itself less while provoking a stronger immune response. [31]

Why it matters. The Danish trial was in adults; RSV's other main victims are babies, and a shot for them has to work differently.

Endpoints News reported three deals in two days. Eli Lilly agreed to pay up to $370m in a research collaboration, BioMarin bought another early-stage bone disease drug, and two small drugmakers merged into one. [32]

Why it matters. A reverse merger is how a listed company with no working drug gets taken over by a private one that has, and the outlet says the run of them is set to continue. [32]

The FDA asked for public comment on a proposed list of medical device accessories that might be classed separately from the machines they attach to, with comments due by 16 October. [27]

Why it matters. An accessory currently inherits the risk class of whatever it plugs into, which can be far stricter than the part deserves.